Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Autor: Geelen IGP; Department of Internal Medicine / Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. i.geelen@erasmusmc.nl., Gullaksen SE; Centre of Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Internal Medicine, Hematology section, Helse Bergen, Bergen, Norway., Ilander MM; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland., Olssen-Strömberg U; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden., Mustjoki S; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Richter J; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Blijlevens NMA; Department of Hematology, Radboud UMC, Nijmegen, The Netherlands., Smit WM; Department of Hematology, Medical Spectrum Twente, Enschede, The Netherlands., Gjertsen BT; Centre of Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Internal Medicine, Hematology section, Helse Bergen, Bergen, Norway., Gedde-Dahl T; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Markevärn B; Department of Hematology, Umeå University Hospital, Umeå, Sweden., Koppes MMA; Department of Hematology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Westerweel PE; Department of Internal Medicine / Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Hjorth-Hansen H; Department of Hematology, St Olavs Hospital, Trondheim, Norway.; Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Janssen JJWM; Department of Hematology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.

Publikováno v: Annals of hematology [Ann Hematol] 2023 Jun; Vol. 102 (6), pp. 1395-1408. Date of Electronic Publication: 2023 Apr 29.